Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors benefit patients with heart failure (HF) with reduced ejection fraction (HFrEF), as well as preserved EFs (HFpEF). Here, SLC5A2 is linked to hydrops fetalis.